Free Trial

Anebulo Pharmaceuticals Q3 2024 Earnings Report

Anebulo Pharmaceuticals logo
$1.31 +0.01 (+0.77%)
(As of 12/17/2024 ET)

Anebulo Pharmaceuticals Earnings Headlines

A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
Benchmark maintains Speculative Buy on Anebulo stock
ANEB Anebulo Pharmaceuticals, Inc.
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (NASDAQ:ANEB), a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

View Anebulo Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings